GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) and similar injectable medications — have transformed obesity medicine. Real clinical evidence shows 12–22% body weight reduction over 60+ weeks of treatment. But these drugs are not appropriate for everyone, and natural approaches deserve serious consideration first or alongside.
GLP-1 medications work by mimicking the natural intestinal hormone that regulates appetite and gastric emptying. Side effects include nausea, vomiting, occasional pancreatitis and possible muscle mass loss with rapid weight reduction. They also typically require lifelong use to maintain results — discontinuation often leads to weight regain.
For individuals with mild to moderate excess weight (BMI 25–32) without diabetes, natural approaches remain first-line: a sustainable Mediterranean-style diet, regular resistance and aerobic exercise, sleep optimisation, and stress management. Adding peptide bioregulators like Cerluten (brain-appetite regulation) and adaptogenic compounds like cordyceps for energy and metabolism can support these foundations.
GLP-1 medications are most appropriate for those with BMI ≥ 30 (or ≥ 27 with weight-related comorbidities like type 2 diabetes), who have tried sustained lifestyle interventions without sufficient result. They should be prescribed and monitored by an experienced clinician, paired with high protein intake and resistance training to preserve lean mass.
The optimal approach is individualised. Discuss with a physician who can evaluate your full clinical picture and integrate the most appropriate combination of lifestyle, supplementation and medication.
